SEC Form 4 · accession 0001610717-26-000293
10x Genomics, Inc. · TXG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Serge Saxonov
Officer — Chief Executive Officer · Director
Period of report
Jun 22, 2026
Accepted (ET)
Jun 24, 2026 · 4:22 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001770787
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF2 | Jun 22, 2026 | S | 8,527 | $33.289 | D | 1,129,853 | D | |
| Class A Common StockF3 | Jun 22, 2026 | S | 9,991 | $34.2815 | D | 1,119,862 | D | |
| Class A Common StockF4 | Jun 22, 2026 | S | 9,821 | $35.3159 | D | 1,110,041 | D | |
| Class A Common StockF5 | Jun 22, 2026 | S | 1,661 | $36.1646 | D | 1,108,380 | D | |
| Class A Common StockF6 | holding | — | — | — | 27 | I | See footnote | |
| Class A Common StockF7 | holding | — | — | — | 213,250 | I | See footnote | |
| Class A Common StockF8 | holding | — | — | — | 71,644 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.
- F2This transaction was executed in multiple trades at prices ranging from $32.75 to $33.74, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F3This transaction was executed in multiple trades at prices ranging from $33.76 to $34.71, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F4This transaction was executed in multiple trades at prices ranging from $34.86 to $35.82, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F5This transaction was executed in multiple trades at prices ranging from $35.98 to $36.24, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F6The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
- F7The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
- F8The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.